Dianthus Therapeutics, Inc. (DNTH)
Market: NASD |
Currency: USD
Address: 7 Times Square
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
📈 Dianthus Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$51.40
-
Upside/Downside from Analyst Target:
194.72%
-
Broker Call:
22
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
100-200%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Dianthus Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-11 (estimated upcoming) | - |
| 2026-03-09 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-11-04 (estimated upcoming) | - |
| 2025-08-06 (estimated upcoming) | - |
| 2025-08-05 (estimated upcoming) | - |
| 2025-05-12 | -0.82 |
| 2025-05-08 | - |
| 2025-05-07 | - |
| 2025-05-06 | - |
| 2025-03-18 | - |
| 2025-03-11 | -0.81 |
| 2024-11-07 | -0.72 |
| 2024-08-08 | -0.51 |
| 2024-08-07 | -0.51 |
| 2024-05-09 | -0.54 |
| 2024-05-08 | -0.54 |
| 2024-03-21 | -0.71 |
| 2024-03-20 | -0.71 |
| 2023-11-09 | -3.78 |
| 2023-11-08 | -3.78 |
📰 Related News & Research
No related articles found for "dianthus therapeutics".
